Aortic Center—Long Island | NYU Langone Health
Cardiac and vascular surgeons at NYU Langone’s Aortic Center —Long Island provide advanced treatment for aortic aneurysm.
Aortic Center—Long Island Doctors | NYU Langone Health
Find a doctor at the Aortic Center—Long Island at NYU Langone.
Aortic Center—Manhattan | NYU Langone Health
Cardiac and vascular surgeons at NYU Langone’s Aortic Center—Manhattan provide advanced treatments to support your aortic health.
Aortic Center—Manhattan Doctors | NYU Langone Health
Find a doctor at the Aortic Center—Manhattan at NYU Langone.
Aortic Dissection | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and vascular surgeons are highly trained in diagnosing and treating aortic dissections.
Aortic Valve Disease | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and interventional cardiologists are highly trained in managing aortic valve disease.
Aortoiliac Occlusive Disease | NYU Langone Health
NYU Langone vascular specialists manage aortoiliac occlusive disease, which limits blood flow to the pelvis and legs.
APOL1 Long-term Kidney Transplantation Outcomes Network
The National Institutes of Health (NIH)-sponsored collaborative APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is charged with prospectively assessing the effects of renal-risk variants (RRVs) in the apolipoprotein L1 gene (APOL1) on outcomes for kidneys from donors with recent African ancestry and the recipients of their kidneys, after deceased- and living-donor renal transplantation. For the purposes of APOLLO, recent African ancestry is defined as individuals with similar genetic make-up to those currently residing in Africa. APOLLO will also study the impact of APOL1 RRVs on the health of living kidney donors with recent African ancestry.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Apps | NYU Langone Health
NYU Langone Health has launched several mobile apps to improve access to patient care and to conduct research studies.